Expanding ligand-receptor interaction networks for axon guidance: Structural insights into signal crosstalk and specificity DOI Creative Commons
Shaotong Zhu, A. Jaworski, Rob Meijers

et al.

Current Opinion in Neurobiology, Journal Year: 2025, Volume and Issue: 92, P. 102999 - 102999

Published: March 20, 2025

Guidance of nascent axons to their targets is mediated by attractive and repulsive cues that activate receptors on the axonal growth cone. The number ligand-receptor interactions implicated in axon pathfinding still expanding, large-scale cell-surface extracellular protein interactome studies have revealed extensive crosstalk between signaling axes once thought act independently. This raises question how apparent promiscuity molecular compatible with specific outcomes effects cone steering. Structural provided insights into modularity binding shown capacity engage multiple ligands. Here, we review recent findings about complexity interaction networks for guidance, structures complexes reveal mechanisms may specify output.

Language: Английский

The role of stromal cells in epithelial–mesenchymal plasticity and its therapeutic potential DOI Creative Commons

Juanjing Wang,

Junmei Peng, Yonglin Chen

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Jan. 20, 2024

Language: Английский

Citations

5
Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs DOI Creative Commons
Fang Ren, Lingfang Wang,

Yuyouye Wang

et al.

Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(8)

Published: Aug. 7, 2024

Endometrial cancer (EC) is a highly heterogeneous malignancy characterized by varied pathology and prognoses, the heterogeneity of its cells tumor microenvironment (TME) remains poorly understood. We conducted single-cell RNA sequencing (scRNA-seq) on 18 EC samples, encompassing various pathological types to delineate their specific unique transcriptional landscapes. Cancer from diverse sources displayed distinct hallmarks labeled as immune-modulating, proliferation-modulating, metabolism-modulating in uterine clear cell carcinomas (UCCC), well-differentiated endometrioid endometrial (EEC-I), serous (USC), respectively. UCCC exhibited greatest heterogeneity. also identified potential effective drugs confirmed effectiveness using patient-derived organoids for each group. Regarding TME, we observed that prognostically favorable CD8

Language: Английский

Citations

5
Reactivation of embryonic genetic programs in tissue regeneration and disease DOI
Hassan Fazilaty, Konrad Basler

Nature Genetics, Journal Year: 2023, Volume and Issue: 55(11), P. 1792 - 1806

Published: Oct. 30, 2023

Language: Английский

Citations

11
Multiplex Digital Spatial Profiling in Breast Cancer Research: State-of-the-Art Technologies and Applications across the Translational Science Spectrum DOI Open Access
Matilde Rossi, Derek C. Radisky

Cancers, Journal Year: 2024, Volume and Issue: 16(9), P. 1615 - 1615

Published: April 23, 2024

While RNA sequencing and multi-omic approaches have significantly advanced cancer diagnosis treatment, their limitation in preserving critical spatial information has been a notable drawback. This context is essential for understanding cellular interactions tissue dynamics. Multiplex digital profiling (MDSP) technologies overcome this by enabling the simultaneous analysis of transcriptome proteome data within intact architecture tissues. In breast research, MDSP emerged as promising tool, revealing complex biological questions related to disease evolution, identifying biomarkers, discovering drug targets. review highlights potential revolutionize clinical applications, ranging from risk assessment diagnostics prognostics, patient monitoring, customization treatment strategies, including trial guidance. We discuss major techniques, applications integration practice, addressing both current limitations. Emphasizing strategic use stratification women with benign disease, we also highlight its transformative reshaping landscape research treatment.

Language: Английский

Citations

4
Blockade of LIF and PD-L1 Enhances Chemotherapy in Preclinical PDAC Models DOI Open Access
Jian Ye, Shuyang Qin,

Angela Hughson

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 204 - 204

Published: Jan. 9, 2025

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC), expecting to be the second leading cause of cancer deaths by 2030, resists immune checkpoint therapies due its immunosuppressive tumor microenvironment (TME). Leukemia inhibitory factor (LIF) is a key target in PDAC, promoting stemness, epithelial-mesenchymal transition (EMT), and therapy resistance. Phase 1 clinical trials showed anti-LIF safe but with limited efficacy, suggesting better outcomes when combined chemotherapy, radiotherapy, or immunotherapy. Methods: We assessed combination chemotherapy (gemcitabine/nab-paclitaxel) dual blockade LIF PD-L1 on growth survival orthotopic spontaneous PDAC models. Flow cytometry scRNA-seq were utilized monitor antitumor response. The role cells was further confirmed depleting these cells, including CD4, CD8, inflammatory monocytes. Results: Sequential treatment significantly improved efficacy compared monotherapy combinations therapies. This chemo/anti-LIF/anti-PD-L1 approach reduced EMT enhanced response, primarily through CD8 T as largely abrogated effect treatment. also shifted macrophages dendritic towards an phenotype. Conclusions: anti-LIF, anti-PD-L1 not only targeted augmented anti-tumor These findings strongly support advancing PDAC.

Language: Английский

Citations

0
An overview of single-cell high-throughput technology in plants DOI
Lucas Auroux, Lim Chee Liew, Mathew G. Lewsey

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 34

Published: Jan. 1, 2025

Language: Английский

Citations

0
Recent advances in immunotherapy for cervical cancer DOI Creative Commons
Aiko Ogasawara, Kosei Hasegawa

International Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

Cervical cancer is the third most common malignant tumor in women worldwide terms of both incidence and mortality. The field cervical treatment rapidly evolving, various combination therapies are being explored to enhance efficacy immune checkpoint inhibitors (ICI) provide new options for patients at different disease stages. Clinical trials involving now conducted following a phase 3 trial with cemiplimab, an ICI, which demonstrated significant improvement prognosis advanced or metastatic patients. These include monotherapy therapy other therapies, chemotherapy, radiation therapy. Furthermore, approaches controlling tumors via system, such as therapeutic vaccination specific antigens cell including chimeric antigen receptor (CAR)-T tumor-infiltrating lymphocytes investigated. Ongoing will continue illuminate optimal strategies combining these addressing challenges associated failure cancer. Herein, we review articles related immunotherapy describe current immunotherapy.

Language: Английский

Citations

0
Spatial-Omics Methods and Applications DOI
Arutha Kulasinghe,

Naomi Berrell,

Meg L. Donovan

et al.

Methods in molecular biology, Journal Year: 2025, Volume and Issue: unknown, P. 101 - 146

Published: Jan. 1, 2025

Language: Английский

Citations

0
TAF7 Directly Targets SAA1 to Enhance Triple-Negative Breast Cancer Metastasis via Phosphorylating E-Cadherin and N-Cadherin DOI Creative Commons
Wanjun Zhang, Jun Wang, Hanning Li

et al.

iScience, Journal Year: 2025, Volume and Issue: 28(3), P. 111989 - 111989

Published: Feb. 10, 2025

Language: Английский

Citations

0
Epithelial-mesenchymal transition in cancer: A focus on itraconazole, a hedgehog inhibitor DOI Creative Commons
Aniruddha Murahar Kulkarni, Prasanna Kumar Reddy Gayam,

Beena Thazhackavayal Baby

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189279 - 189279

Published: Feb. 1, 2025

Cancer, and the resulting mortality from it, is an ever-increasing concern in global health. Cancer stems metastatic progression of disease, by dissemination tumor cells. Epithelial-Mesenchymal Transition, major hypothesis purported to be origin metastasis, confers mesenchymal phenotype epithelial cells a variety contexts, physiological pathological. EMT cancer leads rise cancer-stem-like cells, drug resistance, relapse, malignancy. Inhibition could potentially attenuate mortality. While novel molecules for inhibiting are underway, repurposing drugs also being considered as viable strategy. In this review, Itraconazole focused upon, repurposed molecule mitigate EMT. known inhibit Hedgehog signaling, light shed upon existing evidence, well questions remaining answered.

Language: Английский

Citations

0